April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for patients with valvular heart disease.

The Medicare Hospital Insurance (HI) Trust Fund, which funds Medicare Part A, will only be able to pay full benefits for Medicare beneficiaries until 2026, according to the 2019 annual report from the Medicare Board of Trustees. The Supplementary Medical Insurance (SMI) Trust Fund, which funds Medicare Part B and D, is expected to be adequately financed in all years, but the aging population and rising healthcare costs are projected to grow SMI costs from 2.1 percent of gross domestic product (GDP) in 2018 to approximately 3.7 percent of GDP in 2038.

SCAI SHOCK: Treating the Spectrum of Cardiogenic Shock

SCAI SHOCK: Treating the Spectrum of Cardiogenic Shock aims to provide a comprehensive review of the definition, diagnosis, and management of cardiogenic shock across the spectrum of care, including different etiologies of shock and various presentation settings from the emergency room to cath lab, community hospital to a large academic center. An overview of shock initiatives, the spectrum of shock, and systems of care will be provided.

New guidelines that classified more children as having elevated blood pressure  are better at predicting which kids are likely to develop heart disease when they reach adulthood, according to new research in the American Heart Association’s journal Hypertension. The guidelines were issued by the American Academy of Pediatrics (AAP) in 2017 and endorsed by the American Heart Association.

Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal of Cardiothoracic Surgery1. The prospective, single-arm study included 1,420 patients in 42 hospitals across the United States and represents the largest pericardial-closure study conducted to date. The goal of the study was to evaluate clinical outcomes with pericardial reconstruction using ProxiCor, the company’s proprietary decellularized extracellular matrix (ECM) scaffold designed for the repair of the pericardium.

The U.S. Department of Health and Human Services (HHS) is extending the public comment period by 30 days for two proposed regulations aimed at promoting the interoperability of health information technology (health IT) and enabling patients to electronically access their health information. The new deadline for the submission of comments – June 3, 2019 – will allow additional time for the public to review the proposed regulations.

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models. Their study also shows that this drug can make the heart produce more energy and function more efficiently. The results were published in the April 23 issue of the Journal of the American College of Cardiology.

Long Island Heart: State-of-the-Art Cardiovascular Care for the Clinician

 

Long Island Heart: State-of-the-Art Cardiovascular Care for the Clinician is intended for interventional cardiologists, clinical cardiologists, cardiothoracic surgeons, hospitalists, internists, family practitioners, pulmonologists, nephrologists, emergency medicine physicians, nurses, nurse practitioners, physician assistants, and clinicians who provide care for patients with cardiovascular disease.

A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second major adverse cardiovascular event by almost 50 percent, if they adhere to taking a statin medication as prescribed by their doctors.

Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices that are approved for 3T full-body magnetic resonance imaging (MRI) scans.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now